Unlike several cancer drugs that cause cardiotoxicity, researchers indicate that BET bromodomain inhibitors, such as HDACs, may be a privileged class of cancer drugs that have cardioprotective properties due to the regulation of pro-inflammatory genes [88]. This evidence concerns the gene DNER and cancer.